AG-490 (Tyrphostin B42): Potent JAK2/EGFR Inhibitor for Cancer Research

Executive Summary: AG-490 (Tyrphostin B42) is a high-purity tyrosine kinase inhibitor targeting JAK2, EGFR, and ErbB2, with precise IC₅₀ values (0.1–13.5 μM) in cell-based assays (APExBIO). It disrupts JAK-STAT and MAPK pathways, suppresses cytokine-induced proliferation, and is widely used to study immune cell modulation and cancer signaling (Zhang et al., 2025). AG-490 inhibits M2 macrophage polarization in models of hepatocellular carcinoma, providing insights into tumor immunology. The compound is supplied as a solid, water-insoluble, DMSO/ethanol-soluble reagent at >99.5% purity, suitable for precision research. It is available from APExBIO as catalog number A4139.

Biological Rationale

Tyrosine kinases such as JAK2 and EGFR are central regulators of cell growth, differentiation, and immune responses (Zhang et al., 2025). Dysregulated JAK-STAT and MAPK signaling pathways drive oncogenesis and immune evasion in multiple cancers, including hepatocellular carcinoma (HCC). Exosomal SNORD52, a box C/D snoRNA, was recently shown to enhance M2 macrophage polarization via JAK2/STAT6 activation, enabling tumor progression. Targeted inhibition of these kinases is thus essential for dissecting the molecular mechanisms of tumor microenvironment modulation and for developing translational strategies in oncology and immunopathology.

Mechanism of Action of AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) belongs to the tyrphostin family of tyrosine kinase inhibitors. It directly inhibits JAK2 (IC₅₀ ≈ 10 μM), EGFR (IC₅₀ ≈ 0.1 μM), and ErbB2 (IC₅₀ ≈ 13.5 μM) in vitro (APExBIO). AG-490 blocks ATP binding at the kinase catalytic domain, preventing substrate phosphorylation. This inhibition suppresses downstream activation of STAT1, STAT3, STAT5a/b, and MAPK, resulting in reduced DNA binding activity and transcriptional output in target cells. In B cell precursors from acute lymphoblastic leukemia (ALL) and in IL-2-dependent T cell lines, AG-490 inhibits cytokine-induced proliferation and signal transduction. In T cells derived from mycosis fungoides and in eosinophils, AG-490 blocks JAK2/STAT3 activation, undermining cell survival and inflammatory responses. Recent data demonstrate AG-490’s utility in counteracting exosomal SNORD52-driven JAK2/STAT6 signaling, which mediates M2 macrophage polarization and tumor-supportive immune profiles in HCC (Zhang et al., 2025).

Evidence & Benchmarks

• AG-490 inhibits JAK2 kinase activity with an IC₅₀ of ~10 μM in cell-free kinase assays (APExBIO).
• Suppression of EGFR kinase activity occurs at 0.1 μM, making AG-490 highly potent in EGFR-driven cellular models (APExBIO).
• AG-490 blocks IL-2-induced STAT5a/b phosphorylation and DNA binding in T cell lines, reducing proliferation rates under cytokine stimulation (APExBIO).
• Exosomal SNORD52, enriched in HCC, activates JAK2/STAT6 to polarize M2 macrophages; AG-490 disrupts this axis in vitro (Zhang et al., 2025).
• The molecular structure of AG-490 is defined as C₁₇H₁₄N₂O₃ with a molecular weight of 294.3 g/mol; purity exceeds 99.5% by HPLC (APExBIO).
• AG-490 is insoluble in water but dissolves in DMSO (≥14.7 mg/mL) and ethanol (≥4.73 mg/mL with warming/ultrasonication) (APExBIO).
• Comparable JAK2/STAT pathway inhibitors do not always recapitulate the suppression of M2 macrophage polarization observed with AG-490 in exosomal SNORD52 models (Zhang et al., 2025).

This article extends on 'AG-490 (Tyrphostin B42): JAK2/EGFR Inhibitor for Cancer R...' by providing updated evidence on exosomal SNORD52-driven JAK2/STAT6 signaling in the tumor microenvironment. For advanced mechanisms in translational oncology, see 'AG-490 (Tyrphostin B42): Novel Insights into JAK2/EGFR In...', which this review updates with recent mechanistic findings. For detailed signal transduction protocols, 'Strategic Modulation of the Tumor Microenvironment: Advan...' is complemented here by a focus on reagent specifications and experimental boundaries.

Applications, Limits & Misconceptions

AG-490 is validated for use in preclinical studies investigating:

• JAK2/STAT and EGFR/MAPK signaling in cancer cell lines and primary immune cells.
• Suppression of M2 macrophage polarization in exosome-driven models, particularly in HCC.
• Dissection of cytokine-induced proliferation and downstream transcriptional events.
• Screening for modulators of immunopathological states in vitro.

Common Pitfalls or Misconceptions

• AG-490 does not inhibit all tyrosine kinases; it is selective for JAK2, EGFR, and ErbB2 within reported IC₅₀ ranges.
• It is not effective in water-based formulations due to insolubility; use DMSO or ethanol only.
• Long-term storage of AG-490 solutions is not recommended; prepare fresh aliquots for each experiment.
• The compound is not suitable for clinical or in vivo administration in humans; for research use only.
• Some resistant cell models may exhibit compensatory signaling that bypasses JAK2/EGFR inhibition.

Workflow Integration & Parameters

AG-490 (Tyrphostin B42) is supplied as a high-purity solid (≥99.5%) by APExBIO (SKU: A4139). Dissolve in DMSO at concentrations up to 14.7 mg/mL or in ethanol up to 4.73 mg/mL with gentle warming and ultrasonication. Store dry powder at -20°C; avoid long-term solution storage. Use at empirically determined concentrations, typically 1–20 μM, in cell culture media compatible with DMSO or ethanol. Monitor for cytotoxic effects and verify pathway inhibition by immunoblotting for phospho-STAT and phospho-MAPK targets. For JAK2/STAT6 pathway modulation in macrophage polarization assays, pre-incubate with AG-490 30–60 minutes before cytokine or exosome stimulation.

Conclusion & Outlook

AG-490 (Tyrphostin B42) is a cornerstone tool in signal transduction research. Its selectivity for JAK2, EGFR, and ErbB2 allows precise interrogation of the JAK-STAT and MAPK pathways. The inhibitor is instrumental in elucidating immune cell crosstalk, tumor microenvironment dynamics, and exosome-mediated signaling, as highlighted in recent studies of SNORD52-driven M2 macrophage polarization in HCC (Zhang et al., 2025). Researchers are advised to use AG-490 from APExBIO for high reproducibility and to consult referenced protocols for optimal applications. Ongoing studies will refine its utility in complex models of cancer and immunopathology.